Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancer treatments, has scheduled its Q1 2025 financial results and business updates for Tuesday, May 13, 2025. The announcement will be made before US markets open, followed by a live webcast at 8:00 a.m. EDT.
Investors can access the press release through Adaptimmune's corporate website's investor section and join the webcast at https://www.gowebcasting.com/14032. For those preferring to dial in, the numbers are 1-833-821-0158 (US/Canada) or 1-647-846-2266 (International), with participants advised to connect 5-10 minutes before the start time.
Adaptimmune Therapeutics (NASDAQ: ADAP), un'azienda specializzata in terapie cellulari per il trattamento dei tumori solidi, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 e aggiornamenti aziendali per martedì 13 maggio 2025. L'annuncio sarà diffuso prima dell'apertura dei mercati statunitensi, seguito da una diretta webcast alle 8:00 a.m. EDT.
Gli investitori potranno consultare il comunicato stampa nella sezione investitori del sito corporate di Adaptimmune e partecipare alla webcast tramite https://www.gowebcasting.com/14032. Per chi preferisse partecipare telefonicamente, i numeri disponibili sono 1-833-821-0158 (USA/Canada) o 1-647-846-2266 (Internazionale), con il consiglio di collegarsi 5-10 minuti prima dell'inizio.
Adaptimmune Therapeutics (NASDAQ: ADAP), una empresa de terapias celulares enfocada en tratamientos para tumores sólidos, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 y actualizaciones comerciales para el martes 13 de mayo de 2025. El anuncio se realizará antes de la apertura de los mercados estadounidenses, seguido de una transmisión en vivo a las 8:00 a.m. EDT.
Los inversores podrán acceder al comunicado de prensa en la sección de inversores del sitio web corporativo de Adaptimmune y unirse a la transmisión en https://www.gowebcasting.com/14032. Para quienes prefieran llamar, los números son 1-833-821-0158 (EE.UU./Canadá) o 1-647-846-2266 (Internacional), recomendándose conectarse 5-10 minutos antes del inicio.
Adaptimmune Therapeutics (NASDAQ: ADAP)는 고형 종양 치료에 중점을 둔 세포 치료 회사로, 2025년 1분기 재무 결과 및 사업 업데이트를 2025년 5월 13일 화요일에 발표할 예정입니다. 발표는 미국 시장 개장 전에 이루어지며, 이후 동부 표준시 기준 오전 8시에 라이브 웹캐스트가 진행됩니다.
투자자들은 Adaptimmune 기업 웹사이트의 투자자 섹션에서 보도자료를 확인할 수 있으며, https://www.gowebcasting.com/14032에서 웹캐스트에 참여할 수 있습니다. 전화 참여를 원할 경우, 미국/캐나다는 1-833-821-0158, 국제 전화는 1-647-846-2266번이며, 시작 5-10분 전에 연결하는 것이 권장됩니다.
Adaptimmune Therapeutics (NASDAQ : ADAP), une société spécialisée dans les thérapies cellulaires pour le traitement des tumeurs solides, a programmé la publication de ses résultats financiers du premier trimestre 2025 et mises à jour commerciales pour le mardi 13 mai 2025. L'annonce sera faite avant l'ouverture des marchés américains, suivie d'une diffusion en direct à 8h00 EDT.
Les investisseurs peuvent consulter le communiqué de presse dans la section investisseurs du site corporate d'Adaptimmune et rejoindre la diffusion en direct via https://www.gowebcasting.com/14032. Pour ceux préférant participer par téléphone, les numéros sont le 1-833-821-0158 (États-Unis/Canada) ou le 1-647-846-2266 (International), avec une recommandation de se connecter 5 à 10 minutes avant le début.
Adaptimmune Therapeutics (NASDAQ: ADAP), ein auf Zelltherapien für die Behandlung solider Tumoren spezialisiertes Unternehmen, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 und Geschäftsupdates für Dienstag, den 13. Mai 2025 angekündigt. Die Bekanntgabe erfolgt vor Öffnung der US-Märkte, gefolgt von einer Live-Webcast um 8:00 Uhr EDT.
Investoren können die Pressemitteilung im Investor-Bereich der Adaptimmune-Webseite abrufen und dem Webcast unter https://www.gowebcasting.com/14032 beitreten. Für Telefonteilnehmer stehen die Nummern 1-833-821-0158 (USA/Kanada) oder 1-647-846-2266 (International) zur Verfügung; empfohlen wird, 5-10 Minuten vor Beginn anzurufen.
- None.
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.
The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
###
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251137
FAQ
When will Adaptimmune (ADAP) release its Q1 2025 earnings?
What time is Adaptimmune's Q1 2025 earnings call?
How can I access Adaptimmune's Q1 2025 earnings call?
What does Adaptimmune Therapeutics (ADAP) specialize in?
